Hormone Insight Editorial Team
Clinical archive
Is Indobufen-Based Antiplatelet Therapy Consistent in Diabetic Patients After Stenting? OPTION Analysis
An OPTION post-hoc analysis finds indobufen-based antiplatelet therapy after stenting performs consistently regardless of diabetes status, with a similar bleeding advantage. PICO summary and commentary.
How Does a Text-Message Programme Support Young Adults with Type 1 Diabetes in Care Transition?
A qualitative realist evaluation finds a text-message programme supports type 1 diabetes care transition mainly via knowledge and motivation, with effects varying by individual. PICO summary and commentary.
Tirzepatide Benefits in Obese HFpEF Consistent Regardless of Diabetes Status: SUMMIT Subanalysis
A prespecified SUMMIT analysis finds tirzepatide reduces heart-failure events in obese HFpEF regardless of diabetes status, despite less weight loss with diabetes. PICO summary and commentary.
Text Message Intervention Modestly Improves Glycemic Control in Uncontrolled T2DM: Chinese RCT
A multicentre RCT finds a 12-month text-message programme modestly improves HbA1c and blood pressure in poorly controlled type 2 diabetes, but not LDL. PICO summary and commentary.
How Do Patients Feel About Acupuncture for Diabetic Nerve Pain?
A qualitative study finds most interviewed patients describe positive experiences and symptom relief with acupuncture for diabetic neuropathy, but it cannot prove efficacy. PICO summary and commentary.
Does Enavogliflozin Improve Adipokines Independent of Weight Loss in Type 2 Diabetes?
A phase-3 secondary analysis finds enavogliflozin lowers leptin independent of weight in type 2 diabetes, while the adiponectin rise was weight-dependent. PICO summary and commentary.
Does Dapagliflozin Improve Coronary Blood Flow in Diabetes? DAPAHEART 4-Year Follow-up
The 4-year DAPAHEART follow-up finds dapagliflozin raises coronary flow reserve by 34% and reduces epicardial fat, apparently independent of weight loss. PICO summary and commentary.